Article thumbnail

Multiplex Amplicon Quantification (MAQ), a fast and efficient method for the simultaneous detection of copy number alterations in neuroblastoma

By Candy Kumps, Nadine Van Roy, Lien Heyrman, Dirk Goossens, Jurgen Del-Favero, Rosa Noguera, Jo Vandesompele, Frank Speleman and Katleen De Preter
Topics: Research Article
Publisher: BioMed Central
OAI identifier: oai:pubmedcentral.nih.gov:2879279
Provided by: PubMed Central

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.

Suggested articles

Citations

  1. (2007). A novel locus for dementia with Lewy bodies: a clinically and genetically heterogeneous disorder. Brain
  2. (1999). Altman DG: Measuring agreement in method comparison studies. Stat Methods Med Res
  3. (2008). Array comparative genomic hybridization copy number profiling: a new tool for translational research in solid malignancies. Semin Radiat Oncol
  4. (2006). Broeckhoven C: APP duplication is sufficient to cause early onset Alzheimer's dementia with cerebral amyloid angiopathy. Brain
  5. (2008). Cheung SW: The array CGH and its clinical applications. Drug Discov Today
  6. (2004). Circular binary segmentation for the analysis of array-based DNA copy number data. Biostatistics
  7. (2008). Comparison of different techniques for the detection of genetic risk-identifying chromosomal gains and losses in neuroblastoma. Virchows Arch
  8. (2005). et al.: arrayCGHbase: an analysis platform for comparative genomic hybridization microarrays.
  9. (2005). et al.: Unequivocal delineation of clinicogenetic subgroups and development of a new model for improved outcome prediction in neuroblastoma.
  10. (2002). G: Relative quantification of 40 nucleic acid sequences by multiplex ligation-dependent probe amplification. Nucleic Acids Res
  11. (2006). Genetic risk and transcriptional variability of amyloid precursor protein in Alzheimer's disease.
  12. (2009). International consensus for neuroblastoma molecular diagnostics: report from the International Neuroblastoma Risk Group (INRG) Biology Committee.
  13. Multiplicon the multiplex experts [http://www.multiplicon.com]
  14. (2003). Neuroblastoma: biological insights into a clinical enigma. Nat Rev Cancer
  15. (2008). Novel risk stratification of patients with neuroblastoma by genomic signature, which is independent of molecular signature. Oncogene
  16. (2009). Overall genomic pattern is a predictor of outcome in neuroblastoma.
  17. (2009). Simultaneous mutation and copy number variation (CNV) detection by multiplex PCR-based GS-FLX sequencing. Hum Mutat
  18. SJ: MLPA and MAPH: sensitive detection of deletions and duplications.
  19. (2007). Speleman F: ArrayCGH-based classification of neuroblastoma into genomic subgroups. Genes Chromosomes Cancer
  20. (2009). Speleman F: The emerging molecular pathogenesis of neuroblastoma: implications for improved risk assessment and targeted therapy. Genome Med